Descripción

Additional analyses from the curcumin-ulcerative colitis systematic review address the impact of study quality on pooled estimates. Restricting analysis to high-quality trials maintains the direction of benefit.

Figure 43

Chart

Source Paper

The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systematic Review of Randomized Controlled Clinical Trials.

Nutrients (2020)

PMID: 32751776

DOI: 10.3390/nu12082296

Cite This Figure

![Figure 43: Additional analyses from the curcumin-ulcerative colitis systematic review address the impact of study quality on pooled estimates. Restricting analysis to high-quality trials maintains the direction of benefit.]()

> Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." *Nutrients*, 2020. PMID: [32751776](https://pubmed.ncbi.nlm.nih.gov/32751776/)

<figure>
  <img src="" alt="Additional analyses from the curcumin-ulcerative colitis systematic review address the impact of study quality on pooled estimates. Restricting analysis to high-quality trials maintains the direction of benefit." />
  <figcaption>Figure 43. Additional analyses from the curcumin-ulcerative colitis systematic review address the impact of study quality on pooled estimates. Restricting analysis to high-quality trials maintains the direction of benefit.<br>  Source: Mariana Roque Coelho et al. "The Use of Curcumin as a Complementary Therapy in Ulcerative Colitis: A Systemat." <em>Nutrients</em>, 2020. PMID: <a href="https://pubmed.ncbi.nlm.nih.gov/32751776/">32751776</a></figcaption>
</figure>

Evidencia relacionada

Curcumin para Ulcerative Colitis (UC)

Calificación B · 5 estudios

Curcumin para Crohn's Disease

Calificación C · 3 estudios